This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
Sitagliptin received its initial approval from the U.S. Food and Drug Administration (FDA) on October 16, 2006.
Mechanism of Action of undefined
Sitagliptin works by inhibiting the action of an enzyme called dipeptidyl peptidase-4 (DPP-4). By blocking this enzyme, it allows certain natural hormones, such as GLP-1 and GIP, to remain active in the body for longer. These hormones are crucial in regulating blood sugar levels by increasing insulin release and decreasing glucose production by the liver. Ultimately, this medication helps control blood sugar by enhancing the body's response to elevated glucose levels, aiding in more stable glycemic control throughout the day.
Uses of undefined
Sitagliptin is primarily used to manage type 2 diabetes in adults. It helps regulate blood sugar levels by increasing insulin production in response to meals and decreasing the amount of glucose produced by the liver.
undefined Drug administaration and Dosage available
Sitagliptin is administered orally and is available as tablets in strengths: 25mg, 50mg, 100mg, 10mg/50mg, 10/100mg, 50mg/1000mg and 100mg/1000mg. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition.
Warnings, Precautions and Side Effects of undefined
Warnings
There's a potential risk of pancreatitis after taking Sitagliptin, which can lead to severe abdominal pain, nausea, and vomiting. Although less common compared to some other diabetes medications, it can cause low blood sugar levels, particularly when used in combination with other diabetic drugs. Some individuals may experience allergic reactions to sitagliptin, presenting as skin rash, itching, swelling, severe dizziness, or difficulty breathing. It should be used cautiously in individuals with a history of heart failure, as exacerbation of the condition has been reported in some cases.
Precautions
Be vigilant for symptoms of pancreatitis, such as severe abdominal pain, nausea, or vomiting after taking Sitagliptin. Immediately report any concerning symptoms to a healthcare provider for evaluation. Monitor for signs of allergic reactions like skin rash, itching, swelling, or breathing difficulties. Seek immediate medical assistance if any allergic symptoms arise. Regularly monitor blood sugar levels, especially when combining it with other diabetic medications. Recognize symptoms of hypoglycemia and take necessary precautions to manage low blood sugar. Individuals with a history of heart failure should use sitagliptin cautiously and under medical supervision.
Side Effects
Sitagliptin can have side effects, though not everyone experiences them. Common side effects include upper respiratory tract infections, headaches, and stomach discomfort. Some individuals might experience more severe effects, such as pancreatitis, allergic reactions, or, in rare cases, hypoglycemia (low blood sugar).
Word Of Advice
Stay vigilant for symptoms like severe abdominal pain (a potential sign of pancreatitis), allergic reactions, or low blood sugar after taking Sitagliptin. Promptly inform your healthcare provider if any concerning symptoms arise. Attend scheduled appointments with your doctor to monitor and discuss any questions or issues regarding this medication. Take sit according to your doctor's instructions. Avoid altering the dosage or stopping the medication without consulting your healthcare provider. Inform your doctor about all medications, supplements, or health conditions you have to avoid potential interactions or complications with this medication. Incorporate a balanced diet and regular exercise into your routine to complement its effects in managing diabetes.
Frequently Asked Question
References
- Bayer (Pty) Ltd, Patient information leaflet, [Revised on 15th March 2022], [Accessed on 25th Dec 2023], https://www.bayer.com/sites/default/files/NUBEQA_EN_PIL.pdf#page=2
- Orion Corporation, Orion Pharma, Electronics Medicine Compendium (EMC), [Revised on January 2021], [Accessed on 25th Dec 2023], https://www.medicines.org.uk/emc/files/pil.11324.pdf
- Bayer HealthCare Pharmaceuticals Inc, U.S. Food and Drug Administration, [Revised on July 2019], [Accessed on 25th Dec 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pd
- Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Natural products in cancer chemotherapy: hormones and related agents, 12th edition, 2011, 1707 - 1709.
Disclaimer
The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.